ca/
Simeprevir Approved for Hep C in Canada
Medivir AB announced that Health Canada has approved simeprevir for the treatment of chronic hepatitis C (CHC) genotype 1 infection,
in combination with peginterferon alfa and
ribavirin in adults with compensated liver disease, including cirrhosis, who are treatment-naïve or who have failed previous interferon therapy (pegylated or non‑pegylated) with ribavirin.